In an unprecedented move, Atai Life Sciences, a global biotech company, has invested a significant amount in Beckley Psytech, a company specializing in psychedelic medicine. This strategic investment marks a monumental step towards the development of rapid-acting psychedelic medicines, signifying a potential paradigm shift in mental health treatment.

The U.S. Food and Drug Administration has authorized The Peter Thiel-Backed Psychedelics Company German psychedelics startup Atai Life Sciences to conduct a clinical trial on a nonpsychedelic form of ketamine for treatment-resistant depression.